Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Article
Progressing Skin Penetration
Stanford, Calif. - Conjugation of cyclosporin A to arginine oligomer protein transduction sequences provides a promising method for delivery of the peptide immunosuppressant agent into psoriatic skin. However, further study is needed to characterize the cutaneous bioavailability achieved with that novel delivery platform and to answer the larger question of whether topical cyclosporin A offers a viable therapeutic modality for psoriasis, according to David F. Fiorentino, M.D., Ph.D.
Related Videos
Related Content
